

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 October 2024 (31.10.2024)



(10) International Publication Number
WO 2024/226487 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) A61K 39/00 (2006.01)
A61P 7/06 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:
PCT/US2024/025810

(22) International Filing Date:
23 April 2024 (23.04.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/497,936 24 April 2023 (24.04.2023) US

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(71) Applicant: ZENAS BIOPHARMA, INC. [US/US]; 1209
Orange Street, Wilmington, Delaware 19801 (US).

Published:
— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(72) Inventors: POMA, Allen; c/o Zenas BioPharma, Inc., 1209
Orange Street, Wilmington, Delaware 19801 (US). WANG,
Xiaodong; c/o Zenas BioPharma, Inc., 1209 Orange Street,
Wilmington, Delaware 19801 (US). QUINN, Shauna; c/o
Zenas BioPharma, Inc., 1209 Orange Street, Wilmington,
Delaware 19801 (US).

(74) Agent: ESPINO, Christine G. et al.; Proskauer Rose
LLP, One International Place, Boston, Massachusetts 02110
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)

Safety and Dose Confirmation Period

- N~20
- Up to 14 patients with Primary or secondary wAIHA due to stable autoimmune disorder (Cohort 1)
- Up to 6 patients with secondary wAIHA due to stable lymphoproliferative (Cohort 2)
- Failed one prior wAIHA treatment
- Hemoglobin ≥ 7 to <10 g/dL

FIG. 1

(57) Abstract: The present invention provides compositions and methods of treating and improving the symptoms of AIHA using an antibody or antigen-binding fragment thereof that specifically binds human CD19.

WO 2024/226487 A1